A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
Summary
T cells are a type of immune cell. Like other cells of the body, T Cells can develop cancer. T cell cancers mainly include T cell leukaemia and T cell lymphoma, both of which have a relatively poor prognosis. Currently, patients with relapsed/refractory type (the name given to cancer that reappears or grows again after a period of no changes or signs of cancer) of this leukaemia or lymphoma have limited choices for treatment. CAR-T cells are immune cells that are engineered to target specific cell markers. For example, CAR-T cells targeting the marker CD19 have shown great effectiveness in the treatment of B cell tumors that carry this marker. Here investigators construct a new universal CAR-T design targeting CD7 which is found on the cells of relapsed/refractory type T cell leukaemia and lymphoma and hope to test its safety and efficiency in the treatment of relapsed/refractory type T cell leukaemia and lymphoma.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2023-04-30
- Completion
- 2023-11-01
Outcome
Outcome not reported
Stopped: “No proper participant is found.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Target CD7 CAR-T cells | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | Target CD7 CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | Target CD7 CAR-T cells | Cell therapy | 1.5e+07 cells/kg | Intravenous |